AI-generated summary
The authors report a randomized, double-blind, sham-controlled pilot trial of a brain-gut photobiomodulation therapy in 53 people with mild-to-moderate Alzheimer's disease. Safety and patient compliance were the main outcomes, with the treatment found to be tolerated and mostly mild adverse events balanced between groups, and encouraging but preliminary cognitive trends were noted. The study ended early due to the COVID-19 pandemic.
- Participants
- 53
- Who or what was studied
- Patients with mild-to-moderate Alzheimer's disease
- Limits stated in the abstract
- The study was a small pilot that ended prematurely due to the COVID-19 pandemic, and the authors describe the efficacy findings only as encouraging trends for a larger future trial.
Written by an AI model from this paper’s abstract only and checked automatically against it, but it can still be wrong. It is not medical advice. Read the full paper. See the editorial policy.
Abstract
The full abstract is not shown here because it is protected by the publisher’s copyright. Read it on journals.sagepub.com.
Record from PubMed, a service of the National Library of Medicine.
How to read a trial: what to check before relying on this kind of research.
Terms in this paper: Photobiomodulation, Sham, Photobiomodulation therapy, Pilot study. Each links to its definition in the glossary.
A summary of published research, not medical advice. One study rarely settles a question. See the disclaimer and how to read research.